<b>Conclusions</b>: Aptamers demonstrate high specificity and sustained efficacy in suppressing IL-17A signaling for an in vitro model of spondyloarthritis, with superior performance over antibodies. This evidence concerns the gene IL17A and spondyloarthropathy.